Primary Immunodeficiency Disease Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Clinical phase 3 study to monitor the safety, tolerability, and efficacy of subcutaneous human immunoglobulin (cutaquig ®) administered at modified dosing regimens in patients with primary immunodeficiency diseases
Condition: Primary Immune Deficiency Disorder Intervention: Drug: CUTAQUIG Sponsor: Octapharma Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2019 Category: Research Source Type: clinical trials
